Cardiology Pharmaceuticals May 19, 2025
Getting us closer to understanding GLP-1s’ heart benefits, a post hoc analysis of the SELECT trial suggests that Novo Nordisk’s Wegovy (semaglutide) significantly reduces a patient’s MACE risk in just three months of treatment. Researchers analyzed the SELECT trial data by looking at CV events in the first three to six months following semaglutide treatment […]
Cardiology Pharmaceuticals May 15, 2025
Has a king of the GLP-1s finally been crowned? Full results from the SURMOUNT-5 trial published in NEJM seem to suggest that Eli Lilly’s tirzepatide (Zepbound/Mounjarno) could be better than Novo Nordisk’s semaglutide (Wegovy/Ozempic). Weighing the weight loss benefits of each drug, SURMOUNT-5’s researchers randomized 751 obese patients without T2D to receive either tirzepatide (10mg/15mg) […]
Cardiology Testing May 12, 2025
Knowing which biomarkers to look for is critical to diagnosing and preventing ASCVD, and a new JAMA study suggests calprotectin could be the key to catching ASCVD early. So how does calprotectin predict ASCVD? To answer this, researchers measured calprotectin levels in plasma collected from 2.4k participants during Phase 2 of the Dallas Heart Study […]
